Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
Eli Lilly is presenting Phase 1 clinical data for its first-in-class type II JAK2 inhibitor, AJX-101, at the 2026 European Hematology Association meeting. The drug shows promise for myelofibrosis patients who have developed resistance to existing type I inhibitors.
Why it matters
The presentation of this data at a major medical conference marks a significant milestone in the development of targeted cancer therapies.
INDIANAPOLIS , June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising clinical activity in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor. This first-in-class type II JAK2 inhibitor was designed to selectively bind the type II conformation of the JAK2 kinase in order to potentially provide greater efficacy than existing therapies and a novel treatment option for patients who become resistant to type I JAK2 inhibitors. Lilly recently added this program to its pipeline following the completion of the acquisition of Ajax Therapeutics, Inc.
The content is a standard corporate press release regarding clinical trial progress.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in